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The environment of the gastrointestinal (GI) tract is an extremely complex system
made up of not only host cells, but also many beneficial microbes. Disruption of this
environment can often lead to disorders and health issues. To help balance this system,
probiotics have often been administered to both humans and animals, such as livestock.
This study aimed to determine what beneficial effects a novel strain of Enterobacter
cloacae, strain JD6301, could offer to a host in the presence of an enteric infection with
E. coli O157:H7. Upon administration of JD6301, supplemented animals had overall less
E. coli present in the colon and caecum. Moreover, these animals shed more E. coli than
control groups. Supplemented animals also had increased concentrations of serum
triglycerides one day prior to challenge. Together, these data suggest that Enterobacter
cloacae JD6301 could perform as a novel probiotic providing energy and protection to
the host.
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LITERATURE REVIEW

1.1

Environment of the gastrointestinal tract
The gastrointestinal (GI) tract of mammals is a complex environment composed

of a variety of cells, including host cells and many commensal microflora (Gaggia et al.
2010). In mammals, the amount of commensal bacteria in the gut can exceed the number
of mammalian cells by nearly ten-fold (Sears 2005). The colonization of the mammalian
GI tract with these commensal bacteria begins after birth and is dependent upon a variety
of factors including environment and diet (Guarner and Malagelada 2003, Holzapfel et al.
1998). The bacteria that inhabit the gut play an extremely important role in the overall
health of the host, as they offer both nutritional and protective benefits, and work with the
host to promote immunity (Gaggia et al. 2010, Lebeer et al. 2010, Ohashi and Ushida
2009).
The benefits conferred to the host by the gut microbiota are varied and many
times essential. In regards to nutrition, commensal bacteria are important for the host
since they are responsible for the synthesis of vitamins, the breakdown of certain
substances, and the production of enzymes that aid in digestion (Chaucheyras-Durand
and Durand 2010, Holzapfel et al. 1998). In particular, one study found that animals
whose normal flora have been removed require more calories to maintain their weight
than animals whose normal flora was still intact (Wostmann et al. 1983). This could be
1

due to the fact that, as other studies have found, the gut microbiota also seems to play a
role in the absorption of carbohydrates and lipids, as well as potentially regulating fat
storage (Backhed et al. 2005, Xu et al. 2003).
Microbes in the GI tract are able to offer physically protective benefits to the host
through a variety of mechanisms. For example, bacteria in the gut are capable of the
fermentation of undigested food, which can produce beneficial byproducts, such as short
chain fatty acids (Ohashi and Ushida 2009). These short chain fatty acids can lead to the
production of butyrate that can increase growth of epithelial cells. This epithelial
regulation is lost if the balance of the gut flora is disrupted (Ohashi and Ushida 2009).
The bacteria that reside in the gut are also thought to aid in the upkeep of the mucosal
barrier of the GI tract by promoting mechanisms that increase mucosal defense (Gaggia
et al. 2010, Resta-Lenert and Barrett 2003). Commensal bacteria also protect the host by
blocking binding sites in the GI tract that could be used by pathogens to colonize as well
as by producing antibacterial bacteriocins, which inhibit potential invading pathogens
(Guarner and Malagelada 2003, Ohashi and Ushida 2009). This is emphasized in studies
where mice whose normal flora had been removed were overall more susceptible to
infections with enteric pathogens (Neish 2009).
The gut microbiota also has a profound effect on host immunity, particularly
mucosal immunity (Guarner and Malagelada 2003, Sears 2005). The health of the
intestinal mucosa is extremely important, as it is one of the largest and first physical
barriers between the host and the outside world (Guarner and Malagelada 2003). Some
studies suggest that a mutually beneficial co-evolution occurred, benefiting the host via
the addition of new epitopes to the antigen repertoire, in turn protecting commensals from
2

destruction by host immune cells (Ghosh 2013). Moreover, it has been shown that in
mouse models where the commensal bacteria have been removed from the gut, animals
suffer from a less developed immune system, again with an emphasis on mucosal
immunity (Guarner and Malagelada 2003, Sears 2005).
In innate immunity the normal flora plays a role in the production of angiongen-4,
a bactericidal compound that targets Gram-positive organisms specifically; this not only
plays a role in immunity, but also the development of the gut microbiota (Ghosh 2013, L.
Hooper 2005, Sears 2005). The normal flora of the GI tract influences adaptive immunity
through stimulation of Peyer’s patches and development of lymphocytes in the intestine
(Ghosh 2013, L. Hooper 2005, Sears 2005). Development of Peyer’s patches is
particularly important, as these are germinal centers for B and T cells in the GI tract
(Ghosh 2013, L. Hooper 2005). Stimulation of immunoglobulin A (IgA) production is
another key factor in which the gut microbiota influence the adaptive immunity of the
host, and this effect is lost if the gut microbiota is absent (L. Hooper 2005, Sears 2005).
Because the relationship between the host and gut microbiota is so complex, and
gut microbes play such an important role in host health, dysfunction in the GI tract
environment can lead to disorders and disease (Guarner and Malagelada 2003, Ng et al.
2009). Stress in the forms of physiological and psychological can cause this disruption in
the gut, which in turn leads to potential health issues for the host (Gaggia et al. 2010,
Gareau et al. 2011). Some complications of this disruption include inflammatory bowel
disease, ulcerative colitis, Crohn’s disease, enteric infections and some believe, colon
cancer and autoimmune diseases (Gaggia et al. 2010, Guarner and Malagelada 2003, Ng
et al. 2009). In the past, treating and preventing these disorders often included the use of
3

antibiotics (Gaggia et al. 2010, Hardy 2002, Reid and Friendship 2002, Rolfe 2000).
However, there is growing concern in the wake of an increasing number of antibiotic
resistant strains of dangerous pathogens, which has led to an increase in the use of
probiotics (Gaggia et al. 2010, Hardy 2002, Reid and Friendship 2002, Rolfe 2000).
1.2

Probiotics
Probiotics are usually live yeast or bacterial strains or cell wall components that

provide a benefit to the host when administered, usually by colonizing and balancing the
gut environment via interaction with resident flora (Chaucheyras-Durand and Durand
2010, Fuller 1989, Hakansson and Molin 2011, Ohashi and Ushida 2009). The
FAO/WHO describe probiotics as “a live microbial feed supplement which beneficially
affects the host by improving its intestinal microbial balance”. Initially, probiotics were
used mainly as feed supplements for livestock to promote growth (Galdeano et al. 2007).
This use came in response to an increasing number of antibiotic resistant pathogens,
which led to a call for cessation of the use of antibiotics as growth promoters in the
livestock industry (Gaggia et al. 2010, Hardy 2002). Along with functioning as a
replacement for antibiotic growth promoters in livestock, probiotics are also now widely
used in humans, as they also provide benefits to human hosts (Gaggia et al. 2010,
Galdeano et al. 2007, Hardy 2002).
The concept of using non-pathogenic bacteria as a way to influence health of the
host was first proposed by Metchnikoff in 1907 (Dunne et al. 2001). Metchnikoff
suggested that the ingestion of these helpful bacteria would have a stabilizing effect on
the normal flora of the GI tract, as he believed that the endogenous normal flora might
actually function in a way that is detrimental to the host (Dunne et al. 2001, Holzapfel et
4

al. 1998). Some of the bacterial genera most commonly used as or in probiotics
preparations include Bifidobacterium, Lactobacillus, Lactococcus, and Streptococcus,
although many more genera are now being studied for probiotic potential (Galdeano et al.
2007, Holzapfel et al. 1998). In order for a microorganism to be a successful probiotic, it
must be able to survive in the host environment (Rolfe 2000). Organisms considered for
potential probiotics must be able to survive decreased pH, enzymes in the GI tract, and
bile acids, among other things (Rolfe 2000). Moreover, potential probiotics must also be
able to be produced on a large scale, remain viable for a certain amount of time and must
be safe to the host (Ohashi and Ushida 2009).
Many commercially available probiotic bacterial strains were originally isolated
from humans and exposure to these bacteria can naturally occur very soon after birth
during initial colonization of the GI tract via breast milk (O'Hara and Shanahan 2006).
One of the genera of bacteria most predominately found in the GI tract of breastfed
infants, and found in lesser numbers in the GI tract of formula fed infants, is
Bifidobacterium (Mountzouris et al. 2002, Parracho et al. 2007). Other genera of common
commercially available probiotics that can be isolated directly from breast milk include
Lactobacillus, Lactococcus, and Enterococcus (Lara-Villoslada et al. 2007). Many
studies have found that breastfed infants are better protected from common enteric
pathogens and have overall better health and immunity than infants fed formula
(Mountzouris et al. 2002, Parracho et al. 2007). This natural example of the role of
probiotics and the effect they can have at an integral stage of gut development and
immunity suggests that regular administration of beneficial microbes is a practical
application (Mountzouris et al. 2002, Parracho et al. 2007).
5

1.3

Human use of probiotics
Humans have been consuming preparations containing probiotics for nearly a

century through the consumption of natural remedies (Reid and Friendship 2002).
Modern probiotic preparations have been available to humans for years, with most of
their original success in a small niche in Japan (Dunne et al. 2001). After gaining
popularity, probiotics for human consumption can now be found in many commercially
available foods and dietary supplements including yogurts and cheeses (Bayoumi and
Griffiths 2012, Hakansson and Molin 2011). In Europe alone, there are greater than 1
million people who consume probiotic preparations (Saxelin 2008). Various countries,
including the United States, Canada, and European countries have established legislation
to ensure safety of probiotics used for human consumption (Gaggia et al. 2010). The U.S.
Food and Drug Administration has established that probiotics should meet the Generally
Regarded as Safe (“GRAS”) standards while Europe has enacted similar legislation
known as Qualified Presumption of Safety for probiotics (Gaggia et al. 2010).
Once a bacterial or yeast strain is deemed safe and beneficial for human
consumption, a way to manufacture and deliver the probiotic product must be developed
(Ross et al. 2005). Probiotics must be prepared in a way that they will have an adequate
shelf life, remain viable during preparation, as well as survive inside the host after
ingestion (Ross et al. 2005). To prepare dietary supplements, often taken in the form of a
pill, probiotic strains are often freeze dried (Ross et al. 2005). Along with freeze dried
products in pills, probiotics can also come in the forms of powders or gel capsules
(Saxelin 2008). The most common food preparations of probiotics are usually fermented
foods and dairy products, like yogurts, milk, cheeses and some deserts (Saxelin 2008).
6

The consumption of these probiotic preparations can offer many beneficial effects
to the human host, and perhaps the most prominent is the ability of probiotics to
positively affect the environment and resident flora of the GI tract as well as preventing
colonization of enteric pathogens (Holzapfel et al. 1998). Asahara et. al found that when
certain strains of Bifidobacterium were administered to mice, the presence of these
bacteria in the GI environment decreased the pH of the intestine and increased the acetic
acid concentrations of the gut (Asahara et al. 2004). This change in the gut environment
attenuated the shiga toxin producing strain E. coli O157:H7 by inhibiting shiga toxin
production (Asahara et al. 2004). Another study examining the effect of probiotics on E.
coli O157:H7 found that the presence of Bifidobacterium strains was able to significantly
reduce the amount of E. coli bound to Vero cells, kidney cells isolated from an African
green monkey (Tahamtan et al. 2011). Studies have also shown the probiotic species may
serve to help treat colonization of Helicobacter pylori, a gram-negative bacterium
responsible for gastric distress, ulcers, and potentially cancer (Parsonnet et al. 1991,
Wang et al. 2004). In vitro studies have found that various strains of Lactobacillus were
able to inhibit growth of Helicobacter pylori (Midolo et al. 1995).
Along with improving gastrointestinal health by inhibiting pathogens, probiotic
species also have the ability to beneficially affect other conditions including diabetes,
allergies, and eczema in children (Allen et al. 2014, Gomes et al. 2014). Probiotics have
been shown to be potential adjuvants in treatments for insulin resistance (Andreasen et al.
2010, Ejtahed et al. 2012, Moroti et al. 2012). People with type 2 diabetes have also been
reported to have lower concentrations of two probiotic strains Bifidobacterium and
Faecalibacterium in their GI tract, suggesting their presence may play a role in
7

maintaining the balance that can lead to development of diabetes (Furet et al. 2010).
Studies have also shown that the incidence of eczema in infants can be reduced when
probiotics are administered and that overall, probiotic usage decreases the likelihood that
individuals will develop eczema (Mansfield et al. 2014, West et al. 2009). An in vivo
study found that supplementation with a Lactobacillus strain was also able to ease the
symptoms of children with Crohn’s disease (Guandalini 2002). These results have been
confirmed by countless other studies examining the efficacy of probiotics in treating
various forms of inflammatory bowel diseases, like Crohn’s disease and ulcerative colitis
(Bai and Ouyang 2006, Ng et al. 2009).
1.4

Probiotic use in livestock
Like humans, the GI tract of domestic livestock is a complex environment that

can be regulated and maintained with the use of probiotics (Chaucheyras-Durand and
Durand 2010). Probiotic bacterial strains have been used in the livestock industry as a
way to promote growth and overall health of animals for decades (Fuller 1989). Initially,
the use of probiotics came amid growing fear of an increasing number of antibiotic
resistant strains of dangerous pathogens and downstream human exposure to these
resistant bacteria (Fuller 1989, Gaggia et al. 2010). As early as the 1970s, organizations
around the world began banning the use of antibiotics as growth promoters in the industry
(Thormar 2012). By 2000, the World Health Organization had recommended the full
cessation of all antibiotic therapies that were used as growth promoters alone (Thormar
2012). Although antibiotic therapies are still used, particularly in the United States,
pressure and new alternatives have encouraged those in the industry to discontinue use
slowly (Thormar 2012). To ensure safe products for consumers and to keep animals
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healthy, administration of probiotics has become a common replacement for antibiotic
therapy in order to promote animal immunity, growth, and help prevent infection and
colonization of animals with pathogens (Gaggia et al. 2010). The last point is of extreme
importance as foodborne illnesses account for nearly 76 million illnesses a year (Mead et
al. 1999).
Many of the same genera of bacteria used as probiotics for human consumption
are administered to livestock as well, including Bifidobacterium, Lactobacillus, and
Streptococcus (Dunne et al. 2001). Along with bacterial probiotics, various forms of
yeast probiotic preparations are also often used for domestic livestock (ChaucheyrasDurand and Durand 2010, Gaggia et al. 2010). Some of the yeast strains most commonly
used as probiotics include Saccharomyces cerevisiae and Aspergillus sp. (Gaggia et al.
2010). Probiotics are administered to a variety of domestic livestock, most often pigs,
ruminants (such as cattle), and chickens (Dunne et al. 2001). Probiotics are thought to be
particularly effective in these animals, as they are thought to aid in the prevention of
successful colonization of enteric pathogens like Salmonella, Campylobacter and E. coli
(Gaggia et al. 2010, Reid and Friendship 2002). Along with preventing pathogen
colonization, probiotics can also contribute to the overall health of the animal, which can
lead to increased production of milk or production of better meat (Gaggia et al. 2010,
Reid and Friendship 2002). Preventing the initial colonization of livestock with these
pathogens by using probiotics is a major step in the prevention of downstream infection
of humans and subsequent foodborne disease (Gaggia et al. 2010).
There have been many successful studies on the efficacy of probiotics in various
livestock (Chaucheyras-Durand and Durand 2010, Gaggia et al. 2010). In dairy cattle,
9

yeast like Saccharomyces cerevisiae have been shown to increase milk production, while
in beef cattle, probiotic yeast supplementation led to increased feed to gain ration, final
weight and increases in other growth parameters (Chaucheyras-Durand and Durand
2010). Bacterial probiotics have also been used in cattle and some Lactobacillus
acidophilus strains have been shown to decrease the amount of E. coli O157 in cattle
feces (Chaucheyras-Durand and Durand 2010). Zhao et. al found that after administration
of a probiotic mixture to calves, E. coli was only detected in the rumen fluid for 14 days
compared to 26 days in control calves (Zhao et al. 1998).
Concerning swine, probiotics are found to be particularly useful in pregnant sows as
administration during this time can positively affect the litter (Chaucheyras-Durand and
Durand 2010). After birth, probiotics have also been found to be useful during and after
the weaning process (Chaucheyras-Durand and Durand 2010, Gaggia et al. 2010).
Immediately after weaning, piglets are typically moved to new locations and provided
antibiotics to prevent disease (Reid and Friendship 2002). The antibiotics are now
thought to be a determining factor in many diseases that develop in weaned pigs due to an
insufficient gut microbial community (Reid and Friendship 2002). Probiotics, rather than
antibiotics, may be able to offer protection during the weaning process by balancing and
not disrupting the gut community (Reid and Friendship 2002). Moreover, administration
of probiotics to healthy weaned piglets has led to many beneficial effects, such as weight
gain and more efficient feed utilization (Fuller 1989, Reid and Friendship 2002).
In poultry, Lactobacillus and Bacillus sp. seem to be effective probiotics. In a study
examining the effectiveness of a mixture of three Bacillus strains, birds provided the
probiotic mix had increased digestibility and nutrient retention (Waititu et al. 2014).
10

Other studies found that administration of L. salivarius by oral gavage or by inclusion in
feed led to clearance of Salmonella from chickens tested (Reid and Friendship 2002).
Other studies have found that hens fed probiotics produce eggs with lower yolk
cholesterol levels (Kurtoglu et al. 2004). Probiotic use in chickens has also been shown to
be able to decrease mortality rates due to necrotic enteritis when administration was
begun immediately after birth (Hofacre CL 2003).
1.5

Mechanism of action
Probiotics are able to affect the health of the host in many ways, and as such, there is

not one definitive mechanism of action through which probiotics are able to provide these
benefits (Barzegari et al. 2014, Bayoumi and Griffiths 2012). There are three general
classes in which probiotics activity can be classified: direct antagonism,
immunomodulation, and exclusion (Preidis et al. 2011). These classifications can
themselves contain more than one mechanism by which probiotics are able to benefit the
host, and as such it is essential to understand these mechanisms in order to continue
developing effective products (Ng et al. 2009, Preidis et al. 2011).
By directly antagonizing pathogens, probiotics are able to protect the host from
potentially dangerous enteric infections (Preidis et al. 2011). Probiotic antagonists of
pathogens are usually secreted molecules, such as antimicrobials, or byproducts, like
lactic acid (Asahara et al. 2004, Forestier et al. 2001). Forestier et. al found that the
supernatant of L. casei rhamnosus contained a molecule that was able to inhibit the
growth of a combination of aerobic, anaerobic, Gram-negative and Gram-positive
pathogens by 5 hours in vitro (Forestier et al. 2001). This inhibitory molecule was
determined to be a bacteriocin-like compound secreted by the Lactobacillus strain
11

(Forestier et al. 2001). Others have found that acid by-products of lactic acid bacteria
reduce the pH of the intestine, decreasing the concentration of pathogens like E. coli in
the gut (Asahara et al. 2004, Hutt et al. 2006). Moreover, one study found that acid
produced by probiotics may also act to permeabilize pathogen membranes, and thus make
them more susceptible to other harmful compounds (Alakomi et al. 2000). Bayoumi et.
al. found that molecules secreted by probiotics were actually able to attenuate pathogenic
strains without affecting the growth of these strains, although the mechanism and the
composition of these molecules involved has not been determined (Bayoumi and
Griffiths 2012).
Immunomodulation is another important way in which probiotics are able to provide
benefit to the host (Preidis et al. 2011). Studies have found that children provided lactic
acid bacteria orally had a more robust IgA response to gastroenteritis caused by rotavirus
(Majamaa et al. 1995). Adults receiving an attenuated version of Salmonella typhi as a
vaccination were also provided probiotics had an increased IgA response to the
vaccination (Link-Amster et al. 1994). A study that provided two groups of healthy
adults fermented milk products containing either a Lactobacillus or Bifidobacterium
strain indicated that the presence of these organisms in the intestine increased the
phagocytic activity of cells in peripheral blood against E. coli (Schiffrin et al. 1995).
There does seem to be variation in the effect a strain has on the immune system (Preidis
et al. 2011). One study found that Lactobacillus rhamnosus GG led to an increase in
tumor necrosis factor (TNF), while other studies have found that different strains of
Lactobacillus lead to a decrease in TNF (Iyer et al. 2008, Miettinen et al. 2000, Petrof et
al. 2004). A non-pathogenic strain of E. coli used as a probiotic produces indole, which
12

can modulate the immune system by balancing the production of pro- and antiinflammatory cytokines as well as by increasing secretion of IL-10 (Bansal et al. 2010).
Through competitive exclusion, or simply making the environment of the GI tract
unfavorable to pathogens, probiotics are also known to offer protection to the host
(Preidis et al. 2011). One very common example of exclusion of pathogens occurs when
probiotic strains bind to many sites within the epithelium, leaving less space for
pathogens to attach and colonize (Tuomola et al. 1999). Many strains of commonly used
probiotic organisms are members of the normal flora from either a human or animal host,
and as such most have an affinity to bind to the epithelium of the GI tract making them
effective barriers against pathogens (Gill et al. 2001, Servin and Coconnier 2003). Strains
of two of the most common genera, Lactobacillus and Bifidobacterium, were both found
to adhere well to Caco-2 cells in vitro as well as adhering well in vivo (Servin and
Coconnier 2003). Indole produced by probiotic strain of E. coli increases the expression
of genes responsible for forming tight junctions and the actin cytoskeleton, improving the
intestinal barrier (Bansal et al. 2010).
1.6

Future applications
Modern probiotics can provide many benefits to the host, however, there are

limitations in the knowledge we currently have of these probiotics and mechanisms
responsible for their effectiveness; moreover, little is known regarding how probiotics
may serve as a source of energy to the host (Hakansson and Molin 2011, Ng et al. 2009).
Many probiotics are able to defend the host against pathogenic infection, however, in the
event that infection does occur, the host will go through the metabolically demanding
process of mounting an immune response (Demas et al. 1997). During infection, energy
13

reallocation occurs as the organism must move energy from other biological functions to
promote immunity (Sheldon and Verhulst 1996). This energy demand is also evident
when an animal is undergoing a stressful period which can also require a reallocation of
energy, leaving the animal with less energy to mount an immune response, and thus more
susceptible to illness (Chaucheyras-Durand and Durand 2010, Demas et al. 1997).
Some common stressors of animals can include a change in food, such as when
animals are weaned, a change in environment, or a change in community, among others
(Chaucheyras-Durand and Durand 2010, Demas et al. 1997). Studies have found that
stressors like those mentioned previously can actually cause an animal to initiate an acute
immune response, again sequestering energy away from other essential biological
functions (Colditz 2002, van Heugten et al. 1996) .In vivo studies in chickens whose
immune system had been activated by sheep red blood cells showed that those animals
had higher energy usage coupled with weight loss, despite the fact that those animals
consumed more food than control groups (Demas et al. 1997). Overall, data on energy
usage during stress or immune activation suggest that reallocation of energy may
sometimes be detrimental to the animal and that providing an alternative energy source to
the host may be able to stabilize this allocation process (Demas et al. 1997).
Our lab has recently identified a strain of Enterobacter cloacae, JD6301, that is
capable of producing lipids, stored in inclusion bodies in the cell, at nearly 47% of its cell
weight, classifying it as an oleaginous bacterium (Wilson et al. 2014). Bacteria that are
considered oleaginous accumulate lipids at least 20% of their cell weight in some form of
lipid, such as triglycerides (TAGs) (Alvarez and Steinbuchel 2002). Triglycerides have
long been a known form of stored energy source for eukaryotic organisms, and recent
14

research has shown that some bacteria, like Rhodococcus opacus, also store TAGs as a
form of emergency energy (Alvarez et al. 2000). Enterobacter cloacae strain JD6301 has
many features that suggest it could be utilized as a probiotic, including its ability to grow
at 37°C, tolerate the environment of the host GI tract, and provide energy via TAGs
stored in inclusion bodies near the membrane of the cell (Wilson et al. 2014).
Knowledge of lipids and the role they play in immunity and health is ever growing
(de Pablo and Alvarez de Cienfuegos 2000, Im et al. 2011). The influence of various
forms of lipids on the immune system can be varied ranging from regulating lymphocyte
proliferation to effecting cytokine production (de Pablo and Alvarez de Cienfuegos
2000). Studies have shown that unsaturated fatty acids may modulate the proliferation of
T lymphocytes, leading to an overall reduction in their circulation (de Pablo and Alvarez
de Cienfuegos 2000). Because of their ability to potentially reduce lymphocyte
production, it has been suggested that these unsaturated fatty acids could serve to help
relieve symptoms of some autoimmune diseases (de Pablo and Alvarez de Cienfuegos
2000). Although this application could be useful, it would require diligent supervision as
administration of lipids capable of causing immunosuppression in too large a quantity
could be dangerous (de Pablo and Alvarez de Cienfuegos 2000).
Lipids have also been shown to play a more direct role in immunity via cytokine
regulation and protection against pathogens (Barcia and Harris 2005, Im et al. 2011). In
vivo studies have shown that supplementation of fish oil to mice increased serum
concentrations of interferon gamma when challenged with Listeria monocytogenes (de
Pablo and Alvarez de Cienfuegos 2000). During infection, concentrations of lipids
circulating in the bloodstream can also increase, a condition which can be dangerous if
15

not controlled (Barcia and Harris 2005). The presence of circulating lipids in the
bloodstream, as long as controlled, is also extremely beneficial to the host (Barcia and
Harris 2005). Studies have shown that lipoproteins rich in triglycerides are capable of
binding and neutralizing lipopolysaccharide (LPS) produced by pathogens, and this
complex can act to modulate an immune response (Barcia and Harris 2005). Moreover, in
vivo studies have shown that mice that have inactivated SREBP-1a, a lipogenic
transcription factor, have a deficient innate immune response (Im et al. 2011).
Available data on the role of lipids in immunity and health suggests that extra
lipids made available to the host may be able to offset the metabolic shift during stress
and illness (Barcia and Harris 2005, Demas et al. 1997). The identification of JD6301
presents an opportunity to develop a novel probiotic that would not only function to
protect the host in the traditional aforementioned ways, but also supply an extra source of
potentially useable energy in the form of stored TAGs. Development of this bacterium as
a novel probiotic could bridge the current gap in modern applications of probiotics and
have impacts not only on human and animal health but also industry, with many potential
uses in the food and livestock industries.
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CHAPTER II
GENOME SEQUENCE OF ENTEROBACTER CLOACAE STRAIN JD6301

Previously published:
Wilson JG, French WT, Lipzen A, Martin J, Schackwitz W, Woyke T, Shapiro N,
Bullard JW, Champlin FR, Donaldson JR. 2014. Draft Genome Sequence of
Enterobacter cloacae Strain JD6301. Genome Announc 2.

2.1

Introduction
Enterobacter is a genus of the family Enterobacteriaceae. This family is

composed of Gram-negative rods, which can be found in many different environments,
ranging from soil to humans. Many strains of Enterobacter are known to be resistant to
an array of antibiotics and some are considered nosocomial pathogens (Ren et al. 2010).
Here we report the genome sequence of novel Enterobacter cloacae strain JD6301. This
novel strain was isolated from a co-culture of wastewater collected from a municipal
treatment facility and oleaginous bacteria. The bacterial strain was isolated by subsequent
dilutions into fresh media and finally by culturing onto nutrient agar under aerobic
conditions at 30C. The bacteria were found to grow in a wide variety of conditions,
including temperatures ranging 28-39C and were also found to tolerate slightly acidic
conditions (pH 4.5). On blood agar JD6301 exhibits alpha hemolysis. MacConkey and
Eosin Methylene Blue agar confirm that it is capable of utilizing lactose. It is oxidase
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negative, and exhibits gas production in triple sugar iron agar. The most unique feature of
JD6301 is its ability to form inclusion bodies, which has not been previously
characterized for this species. The lipid weight of this strain was found to constitute
approximately 50% of the total cellular weight, suggesting that these inclusion bodies
may contain lipids.
A draft of the genome of Enterobacter cloacae JD6301 was generated at the DOE
Joint Genome Institute (JGI) using Illumina HiSeq 2000 technology. To remove any
artifacts following Illumina sequencing, raw data was passed through DUK, a program
developed by JGI. Illumina reads were assembled using Velvet v. 1.104 (Zerbino and
Birney 2008), 1-3 kb simulated paired ends were created from Velvet contigs using
wgsim (https://github.com/lh3/wgsim), and Illumina reads were then assembled with
simulated pairs using Allpaths-LG v. r42328 (Gnerre et al. 2011). The assembly yielded
53 contigs in 49 scaffolds. For genome annotation, Prodigal was used to identify genes
(Hyatt et al. 2010). This was followed by manual curation using GenePRIMP (Pati et al.
2010). tRNAScanSE (Lowe and Eddy 1997) was used to find tRNA genes, while rRNA
genes were identified using SILVA (Pruesse et al. 2007). INFERNAL
(http://infernal.janelia.org) was used to identify non-coding RNAs. Other gene
predictions and manual function annotation were performed using the Integrated
Microbial Genomes (IMG) platform (http://img.jgi.doe.gov) developed by JGI
(Markowitz et al. 2009).
The completed genome of strain JD6301 is 4,772,910 bp in length. There are an
estimated 4,288,696 coding bases and the G+C content is near 53%. There are a total of
4,509 protein-coding genes, with 84.91% predicted to have a function. Of the genes
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identified, 4,246 match to Enterobacter cloacae. Multiple multidrug efflux pumps were
identified, which is common among Enterobacter cloacae (Ren et al. 2010). Genes
associated with a Type IV secretion system were also identified, another common feature
of Enterobacter cloacae (Liu et al. 2013). Proteins associated with pilus production were
also identified, which may have contributed to the inclusion bodies observed in this novel
strain via exchange of genetic material. The novel aspect of an Enterobacter sp. strain
producing large quantities of lipids warrants further investigation.
2.2

Nucleotide sequence accession number
This draft genome sequence has been deposited in the IMG system as accession

number 20133 and GenBank under accession number JDWH00000000.
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CHAPTER III
ENTEROBACTER CLOACAE JD6301 ALTERS THE METABOLIC RESPONSE OF
MICE WHEN CHALLENGED WITH ENTERIC PATHOGEN E. COLI O157:H7

3.1

Introduction
The gastrointestinal (GI) tract of mammals is a complex microbial ecosystem that

is involved in providing many benefits to the host, including aiding in digestion,
contributing to the gut immune system, and preventing the successful colonization of
potential pathogens (Chaucheyras-Durand and Durand 2010). The gut also plays an
important role in overall health of mammals (Gaggia et al. 2010). Stress that affects the
gut microbiota can lead to an imbalance in the gut and subsequently increased
susceptibility to pathogens or gastrointestinal disorders, such as irritable bowel syndrome
(Gaggia et al. 2010). This delicate balance between the commensal microbes and the host
is often regulated by probiotics in both humans and livestock (Chaucheyras-Durand and
Durand 2010, Ohashi and Ushida 2009).
Probiotics are classified as viable cells or cell components that provide a health
benefit to the host (Asahara et al. 2004). These supplements are typically used to
influence the gut mucosal immunity and may provide protection against invading
pathogens. However, limitations exist in the usefulness of probiotics during infections.
This is primarily due to the energy required by the host to mount an efficient immune
response, which is provided through diet and fat (lipid) reserves (Segerstrom 2007).
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Infections increase the energy demand upon the host, which leads to shifts in energy
metabolism and utilization, and often results in increases in glucose utilization and the
synthesis of very low-density lipoproteins (van Heugten et al. 1996). Loss of appetite or
insufficient energy reserves can affect overall energy availability, thereby negatively
impacting the outcome of disease (van Heugten et al. 1996). This is commonly observed
in piglets during the weaning process; these animals often experience periods of
decreased feed and water intake, limiting the energy available to them (Lalles et al.
2007). This can also lead to disruption of the gut environment, making these animals
more susceptible to infection (van der Peet-Schwering et al. 2007).
Along with their vital role in metabolism, it has also become clear that lipids have
an integral role in innate immunity. In response to infections, particularly the presence of
lipopolysaccharides (LPS), the liver increases synthesis of lipoproteins rich in
triglycerides (Barcia and Harris 2005). Lipids are capable of binding and neutralizing
endotoxin (LPS), reducing infectious capacity. Additionally, lipids have also been shown
to have an activating effect on the innate immune response (Barcia and Harris 2005). In
vivo studies in mice have shown that animals lacking a key lipogenic transcription factor
have deficient innate immune responses. While these mice were able to resist a challenge
with LPS, they were unable to mount an efficient immune response when challenged with
a bacterial pathogen orally (Im et al. 2011). These responses correlate with deficient
innate immunity and exhibit the important role lipids play in immunity (Im et al. 2011).
Here, we utilized a novel approach of providing additional lipids through bacteria
that could improve the availability of energy and also potentially act as a traditional
probiotic. The Enterobacter cloacae strain JD6301, which produces lipids at 47% of its
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cell weight (Wilson et al. 2014), was found to increase the amount of lipids available to
an animal and also altered the metabolic response of mice when challenged with
Escherichia coli O157:H7. Animals provided JD6301 also had increased serum
concentrations of interleukin-1α following exposure to E. coli (p < 0.05), a key cytokine
in the innate immune response (Cybulsky et al. 1986). Moreover, JD6301 also
demonstrated the ability to survive in the GI tract and potentially prevent successful
colonization of E. coli O157:H7.
3.2
3.2.1

Materials and methods
Bacterial strain and growth conditions
Enterobacter cloacae strain JD6301 was routinely cultured in mineral salts

medium (MSM) with 25 ug/ml novobiocin at 37C. For supplementation of the bacteria
to the water, samples were cultured for 24 hr, after which 1x1010 CFU (~25ml) were
stored at -20C in 20% glycerol. On the day of administration, frozen aliquots were
thawed, centrifuged for 10 min at 8000 x g to remove glycerol, and resuspended in 150
ml sterile Ultrapure water (Millipore) supplemented with 0.3% xanthan gum. Escherichia
coli O157:H7 (ATCC 43895) transformed with the plasmid pXEN-13 was cultured in
nutrient broth (NB) supplemented with 100 µg/ml ampicillin (amp) at 37C (Free et al.
2012).
3.2.2

Animals
Forty BALB/c mice 5-6 weeks of age were purchased from Harlan Laboratories

and allowed to acclimate to the animal facility at Mississippi State University for 5 days.
During this period mice were provided sterile water and irradiated chow ad libitum. Mice
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were separated into two treatment groups (n=20 mice/treatment with 4 mice/cage). Group
1 received sterile water supplemented with 0.3% xanthan gum; group 2 received sterile
water supplemented with Enterobacter cloacae JD6301 (109 CFU/mL) and 0.3% xanthan
gum. Fresh water bottles were prepared every other day; bottles were weighed to measure
rates of water disappearance. All animal studies were conducted in accordance with
procedures approved by the Mississippi State University Institutional Animal Care and
Use Committee (Protocol #12-066).
3.2.3

E. coli O157:H7 infection model
Mice were provided PBS or JD6301 for the duration of the study. Mice were

provided JD6301for 6 days prior to E. coli challenge with continued supplementation
until sacrifice. On d 0 all mice were challenged with E. coli O157:H7 at a concentration
of 1x1010 CFU via oral gavage (Gagnon et al. 2006). One cage from each group (n=4
mice per group) was humanely sacrificed on d -1, 1, 2, 3, and 4. Prior to being sacrificed,
blood was collected from the mice via retro orbital bleed and serum was separated using
a StatSpin StatSampler blood collection system (TP5G, Iris Sample Processing, Inc.,
Westwood, MA) and stored at -20C. Feed intake and body weights were collected on the
day of sacrifice.
3.2.4

GI tract/fecal collection and contents enumeration
Sections of the GI tract (caecum and colon) were homogenized in 1.5 ml tubes

with 2.3 mm zirconia/silica beads (11079125z; Biospec Products, Bartlesvile, OK) and 1
ml phosphate buffered saline (PBS) in a BeadBug micro tube homogenizer (Benchmark
Scientific, Edison, NJ) for 30 sec at 4,000 rpm. Samples were diluted in PBS and plated
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on nutrient agar (NA) supplemented with 75 µg/ml novobiocin to select for Enterobacter
cloacae JD6301 and NA with 100 µg/ml ampicilin (NA amp) to select for E. coli.
Colonies were enumerated following a 16 h incubation at 37C.
Fecal samples were collected on d 1, 2, and 3. Single pellets were homogenized in
1 ml of PBS, serially diluted and plated on NA amp to select for growth of E. coli.
Colonies were enumerated following a 16 h incubation at 37C.
3.2.5

Serum analysis
Serum was collected and analyzed for concentrations of triglycerides (TAGs)

using the serum triglyceride determination kit (TR100, Sigma Aldrich, St. Louis, MO).
Triglycerides were analyzed per manufacturer’s instructions using 10 µl of serum. After
preparation, samples were analyzed with a Biotek Synergy HT plate reader immediately.
Serum TAGs were compared between mice provided JD6301 supplemented water and
PBS control animals.
Serum cytokine concentrations were analyzed using the Milliplex mouse
cytokine/chemokine multiplex assay (MCYTOMAG-70K-PMX, EMD Millipore,
Billerica, MA). The serum was prepared per manufacturer’s instructions using 25 µl of
sample. Following preparation, all samples were analyzed immediately using Luminex
xMAP technology (Millipore). Cytokine concentrations were compared between JD6301
supplemented and non-supplemented groups to determine differences in cytokine
production. Twenty-six cytokines/chemokines were analyzed in triplicate.
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3.2.6

Duration of intestinal persistence of Enterobacter cloacae JD6301
Twenty 5-6 week old Balb/c mice acclimated to the facility were separated into

five cages (n= 4 mice/cage). JD6301 was provided via water to mice in each cage for 6
days prior to removal. On d 0, JD6301 was removed and mice were provided sterile
water. Serum and intestinal samples were collected from mice from one cage on d 0, 1, 2,
3, and 4 and analyzed as stated in E. coli challenge section with the exception of
intestinal contents only being tested for the presence of JD6301. All animal studies were
conducted in accordance with procedures approved by the Mississippi State University
Institutional Animal Care and Use Committee (Protocol #12-066).
3.2.7

Statistical analysis
A Student’s t test was performed to determine statistical significance. P values of

less than 0.05 were considered statistically significant.
3.3
3.3.1

Results and discussion
Enumeration of GI tract contents and fecal samples
All mice that were provided Enterobacter cloacae JD6301 had populations

present in the cecum and colon, confirming that JD6301 remains viable in the host
environment. Prior to challenge, JD6301 was detected in nearly equivalent amounts in
each section collected. However, after challenge with E. coli O157:H7, JD6301
concentrations fluctuated in all sections (Fig. 1). This suggests that the presence of E. coli
O157:H7 may have some effect on the viability of JD6301. One potential explanation for
fluctuations in JD6301 concentrations post-challenge could be interactions between
JD6301 and E. coli. This potential interaction suggests JD6301 may act as a traditional
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probiotic by preventing the successful binding of a pathogen to the host GI tract, thereby
preventing establishment of infections.
E. coli O157:H7 was detected in the aforementioned sections of the GI tract in all
animals post-challenge. Treated and control animals had comparable concentrations of E.
coli in the colon and cecum d 1-3 (Fig. 3.1). However, by d 4, treated animals had, on
average, reduced concentrations of E. coli in both the cecum and the colon. There was an
increase (p<0.05) in E. coli populations in the cecum of untreated animals from d 1 to d
4. Conversely, there was no difference (p=0.9) of E. coli populations in treated animals
from d 1 to d 4. These data could suggest that the presence of JD6301 prevents E. coli
from colonizing within the cecum. This is of particular interest due to the fact that in both
ruminants and non-ruminants, including humans, E. coli colonization often occurs at the
cecum (Baines et al. 2008, Rhee et al. 2011). The increase in JD6301 populations in this
section suggests JD6301 may be able to compete for resources in this key area of the GI
tract, potentially preventing successful colonization of pathogens like E. coli.
Fecal shedding of E. coli O157:H7 was monitored post-challenge (Fig. 3.1). On d
1 comparable E. coli shedding was noted in control and treatment groups. By d 3, mice
provided JD6301 had on average more shedding of E. coli than animals in the control
group. Controls animals had a significant increase in E. coli populations in the cecum on
d 4, and decreased fecal shedding of E. coli by d 3. Conversely, mice provided JD6301
had increased fecal shedding of E. coli by d 3 and decreased concentrations of E. coli in
the cecum and colon by d 4. This suggests that JD6301 interfered with the successful
adherence of E. coli to the intestinal lining.
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GI tract sections and fecal shedding

GI tract sections ileum (black), caecum (pattern), and colon (gray) were collected and
contents were homogenized and plated to detect the presence of either JD6301 or E. coli.
Presence of JD6301 was detected in all sections prior to E. coli challenge, with
fluctuations post challenge (A). Cecum (B) and colon (C) sections of mice showed that
by d 4, control animals () had an overall higher burden of E. coli compared to animals
provided JD6301 (). Fecal shedding was detected via selective plating (D).

3.3.2

Serum TAGs and cytokine analysis
Serum was analyzed for both TAGs and cytokine/chemokine levels. Animals

provided JD6301 had nearly double the concentration of serum TAGs on d -1 compared
to non-treated groups. By d 1, control animals had an increase in concentrations of serum
TAGs (p<0.05), while there was not a significant change in supplemented animals (Fig.
3.2). By d 4, the serum concentration of TAGs for all groups had returned to
concentrations equivalent to those prior to E. coli challenge. Increased serum TAGs of
treated animals on d -1 indicate that JD6301 may be providing additional usable energy
to host animals upon administration. The significant increase of serum TAGs in control
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animals on d 1 could be indicative of the metabolic burden placed on those animals in the
presence of enteric pathogen challenge. Compared to control animals, mice provided
JD6301 did not have a significant increase in serum TAGs on d 1, which suggests that
these animals did not have to produce as many endogenous TAGs, but rather were able to
utilize TAGs provided by JD6301. The decreased need to transport endogenous TAGs to
the bloodstream during infections could demonstrate the overall lessened metabolic
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burden placed on animals provided JD6301.
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Figure 3.2

Serum triglyceride concentrations

Serum triglyercide concentrations were determined using a serum triglyceride kit using
10 µL of serum. One day prior to E. coli challenge, JD6301 supplemented animals ()
had a higher concentration of serum TAGs than control () animals. By d 1 control
animals had higher (p < 0.05) concentrations of serum TAGs.

Cytokine analyses indicated that by d 1, animals provided JD6301 had increased
concentrations of the cytokine interleukin-1α (IL-1α) compared to control animals.
Although JD6301 treated animals did not have a significant increase in serum TAGs
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upon challenge with E. coli, those animals were still able to mount a response, as seen by
the increase (p<0.05) of IL-1α one day after challenge compared to non-treated animals
(Fig. 3.3). Additionally, JD6301 supplemented animals did not have an increase in IL-1α
prior to challenge, confirming this was not a prolonged inflammatory response caused by
JD6301, but rather an acute response prompted by challenge with E. coli. IL-1α is
member of the Interleukin 1 family, which has 11 members total (Sims and Smith 2010).
IL-1α is a cytokine that has widespread expression and induces an inflammatory response
(Sims and Smith 2010). In vivo studies have shown that IL-1α also plays an important
role in the recruitment of neutrophils (Barry et al. 2013). It will be important for future
studies to examine the role JD6301 induced production of IL-1α may have in neutrophil
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Ratio of IL-1α

Cytokine analysis was performed using Luminex technology. By d 1, JD6301
supplemented animals (gray) had a higher ratio of IL-1α present in the serum compared
to control (black) animals.
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3.3.3

Intestinal persistence of Enterobacter cloacae JD6301
To determine how often administration is required for JD6301 to remain present

in the gut, the duration of intestinal viability was analyzed. Enterobacter cloacae JD6301
was detected in all intestinal sections collected from persistence study animals on d 0 and
1. However, by d 2, JD6301 was not detected in any of the sections collected (Fig. 3).
This suggests that JD6301 can survive within the GI tract for no more than 48 hours.
Serum TAG concentrations correlate with the increase and then decrease in JD6301 in
the GI tract of persistence animals (Fig. 3.4). Persistence study animals sacrificed on d 0
had similar serum TAG concentrations as animals in the E. coli challenge on d -1 (Fig.
3.4). Within three days post-removal of JD6301, serum TAG concentrations had
decreased below d 0 concentrations and continued to decrease on d 4, which was
significantly less than d 0 concentrations (p = 0.05). Overall, these data suggest that while
JD6301 is capable of providing benefits to the host, in order for JD6301 to confer these
benefits, it must be repeatedly administered.
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1

Intestinal presence of JD6301 and serum TAG concentrations

Persistence of Enterobacter cloacae JD6301 in the ileum (black), cecum (pattern), and
colon (gray) sections of the GI tract. JD6301 was not detected in any section 48 hours
after removal (A). Serum triglyceride concentrations of animals in the persistence study
decreased after the removal of JD6301 (B).
3.4

Conclusion
The metabolic shift towards immunity animals undergo during periods of stress or

infections leaves a deficiency in the energy available for other essential processes for
survival. Our novel probiotic may be able to provide useable energy to animals during
energy deficient states. Our data suggest that Enterobacter cloacae JD6301 may not only
act as a novel source of useable energy, but also as more traditional probiotic by
preventing the successful colonization of pathogens, like E. coli O157:H7. Providing
JD6301 to animals was able to increase concentrations of serum TAGs, decrease overall
colonization of E. coli in the caecum and colon, and promote increased levels of the
cytokine IL-1α. While further study is needed to enumerate its mechanism of action,
Enterobacter cloacae JD6301 may be useful as a tool to combat losses of livestock not
only due to infection, but also starvation and energy depletion.
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CHAPTER IV
CONCLUSION

The gastrointestinal (GI) tract of mammals is an extremely complex environment
and an integral part of health and immunity (Gaggia et al. 2010). As such, it is important
to maintain the integrity and health of the GI tract, including the resident bacteria, in
order to ensure its benefits are conferred to the host (Galdeano et al. 2007, Guarner and
Malagelada 2003). Probiotics are often used to improve the health and immunity of the
host (Gaggia et al. 2010, Hardy 2002). Probiotics are now widely used both in humans
and animals and many benefits have been associated with their use (Reid and Friendship
2002). There are however gaps in knowledge of probiotic benefits, particularly related to
their ability to provide useable energy to the host during metabolic shifts induced by
stress or infection (Demas et al. 1997).
The literature reviewed in Chapter I examined the important role of the GI tract of
mammals and how dysfunctions in this environment can lead to disease. Moreover, the
role of probiotics and the current gaps in application of modern probiotics was also
discussed. There are many different stressors that can lead to dysfunctions within the GI
tract, including changes in diet, environment, and disease (Guarner and Malagelada 2003,
Ng et al. 2009). These dysfunctions can affect the health of the host, and thus probiotics
have often been used to balance the gut environment (Gaggia et al. 2010, Galdeano et al.
2007). Despite the benefits many probiotics offer, there are limitations in the ability of
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current probiotics to offer additional energy to the host`. The benefits of additional
energy to the host would be particularly useful during energy deficient periods when
animals do not have available energy to continue normal metabolic processes
(Chaucheyras-Durand and Durand 2010, Sheldon and Verhulst 1996). Through the use of
lipids stored in inclusion bodies, Enterobacter cloacae JD6301 could supply the host
with a potentially useable source of energy and provide a benefit to overall immunity
(Barcia and Harris 2005, Im et al. 2011, Wilson et al. 2014).
The genomic sequence and data presented in Chapter II confirm that JD6301 has
many traits that would make it an acceptable probiotic. It is able to survive in a range of
temperatures, including those of potential hosts. Moreover, it has shown some resistance
to acidic conditions. These are all traits that would be beneficial to JD6301 as a probiotic,
as perhaps the most important consideration for potential probiotic strains are their ability
to remain viable in the host (Ross et al. 2005). The inclusion bodies containing lipids
contained by Enterobacter cloacae strain JD6301 are yet another feature that could make
it an extremely useful tool as a novel probiotic. The lipids stored in these inclusion bodies
could potentially act as useable energy when provided to a host in an energy-depleted
state.
The in vivo study presented in Chapter III demonstrated the ability of
Enterobacter cloacae strain JD6301 to act as a potential probiotic. Through
supplementation via water, mice provided JD6301 had an overall more robust immune
response and had lower amounts of pathogen present in the intestines when challenged
with E. coli O157:H7. Animals in supplemented groups also had increased fecal shedding
of E. coli compared to non-supplemented controls. Additionally, JD6301 was detected in
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all sections tested throughout the study, with the exception of day 2, where
concentrations varied. Altogether, these data suggest that JD6301 has the potential to act
via a more traditional mechanism of action and inhibit the successful binding and
subsequent colonization of a pathogen in the host GI tract.
In addition to its ability to affect pathogen colonization, JD6301 also seemed to
induce a more robust immune response in animals supplemented. Mice provided JD6301
had an increased concentration of serum TAGs 1 day prior to challenge with E. coli. This
increase in serum TAG concentration could be associated with the presence of JD6301
and the lipids potentially released by this bacterium to be used by the host. This could be
particularly useful, as lipids play an important role in immune modulation (de Pablo and
Alvarez de Cienfuegos 2000). JD6301 was also shown to affect cytokine production, as
mice provided this bacterium had higher concentrations (p<0.05) of IL-1α detected 1 day
after challenge. This supports other data that showed that certain fatty acids were able to
modulate cytokine response, suggesting lipids could play a role in overall cytokine
regulation (de Pablo and Alvarez de Cienfuegos 2000). Together, these data suggest that
Enterobacter cloacae strain JD6301 has the potential to function as both a traditional
probiotic, by inhibiting pathogens, and novel probiotic by providing energy to the host
via lipids stored in lipids inclusion bodies. While more research is needed to elucidate the
mechanism of action of JD6301, the development of this bacterium as a probiotic could
initiate the development of many other products that could be beneficial to both human
and animal health.
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FEED INTAKE, WATER DISAPPEARENCE AND MOUSE BODY WEIGHTS
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A.1

Feed intake throughout study
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Figure A.1

Feed intake

Feed intake was monitored during the study. Prior to being added to cages, feed was
weighed and recorded. On the day of sacrifice feed weight was measured again to
determine feed intake throughout study. There was no difference in feed intake between
control (black) and JD6301 supplemented (gray) groups.
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A.2

Water disappearance throughout study
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Figure A.2

Water disappearance

Water disappearance was measured every other day as water bottles were replaced.
Presented data represents rates of water disappearance for the same group for control
(black) and JD6301 supplemented (gray) throughout entire study.
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A.3

Mouse body weights
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Figure A.3

Mouse body weights

Weights of each mouse were taken at time of sacrifice. No difference was seen in weights
of mice in control (black) groups compared to JD6301 supplemented (gray) groups on
any day throughout study.
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CYTOKINE ANALYSIS
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B.1

Supplemental cytokine analysis

Table B.1

Analyzed cytokines that showed variations in immune response between
control and JD6301 supplemented animals
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